The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter

被引：0
|
作者：
Leon, Leticia G. [1 ,2 ]
Funel, Niccola [1 ]
Peters, Godefridus J. [3 ]
Avan, Amir [4 ,5 ]
Vistoli, Fabio [6 ]
Boggi, Ugo [6 ]
Giovannetti, Elisa [1 ,3 ]
机构：
[1] Univ Pisa, Canc Pharmacol Lab, AIRC Start UP Unit, I-56124 Pisa, Italy
[2] Univ La Laguna, Ctr Biomed Res Canary Isl, Inst Tecnol Biomed, E-38207 San Cristobal la Laguna, Spain
[3] VU Univ Med Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
[4] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Sch Med, Mashhad, Iran
[5] Mashhad Univ Med Sci, Canc Res Ctr, Sch Med, Mashhad, Iran
[6] Univ Pisa, Div Gen & Transplant Surg, I-56124 Pisa, Italy
来源：
CLINICAL CANCER RESEARCH | 2016年 / 22卷 / 10期
关键词：
PANCREATIC-CANCER; ANTITUMOR-ACTIVITY;
D O I：
10.1158/1078-0432.CCR-16-0259
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2594 / 2594
页数：1
相关论文
共 50 条
  • [41] Targeting MEK1/2 inhibitor resistance in RAS-mutated cancers.
    Kinsey, Conan
    Camolotto, Soledad
    Boespflug, Amelie
    Gullien, Katrin
    Truong, Amanda
    Foth, Mona
    Shea, Jill
    Seipp, Michael
    Yap, Jeffrey
    Burrell, Lance
    Lum, David
    Whisenant, Jonathan
    Cavalier, Courtney
    Rehbein, Kaitren
    Cutler, Stephanie
    Afotler, Kajsa
    Welm, Alana
    Welm, Bryan
    Scaife, Courtney
    Snyder, Eric
    McMahon, Martin
    CANCER RESEARCH, 2020, 80 (19) : 23 - 23
  • [42] Targeting MEK1/2 signaking cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
    Tai, Yu-Tzu
    Kim, Kihyun
    Fulciniti, Mariateresa
    Soydan, Ender
    Song, Weihua
    Li, Xian-Feng
    Rumizen, Matthew
    Nahar, Sabikun
    Burger, Peter
    Hideshima, Teru
    Richardson, Paul
    Munshi, Nikhil
    Clark, Ann
    Goutopoulos, Andreas
    Rastelli, Luca
    Kenneth, Kenneth
    CANCER RESEARCH, 2009, 69
  • [43] AZD6244 (ARRY-142886), a potent and selective MEK1/2 inhibitor, enhances tamoxifen sensitivity in resistant ER-positive/HER2-positive breast cancer cells with constitutively elevated MEK1/2
    Zhou, Yamei
    Benz, Chrisptopher C.
    CANCER RESEARCH, 2006, 66 (08)
  • [44] Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: Results from a phase 2 trial
    Wang, JinHu
    Li, Wenbin
    Zeng, Kang
    Lin, Xiaoxi
    Li, Yanling
    Guan, Zhonghai
    Kang, Zhuang
    Li, Changxing
    Hu, Xiaojie
    Ma, Yaohui
    Wu, Zhuli
    Wang, Xingli
    Han, Pu
    Lin, Hongmei
    Zhong, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Mek1, but not Mek2, alters epidermal growth and differentiation
    Scholl, FA
    Dumesic, PA
    Charron, J
    Khavari, P
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2004, 122 (03) : A77 - A77
  • [46] Targeting MEK1/2 Signaling Cascade by AS703026, a Novel Selective MEK1/2 Inhibitor, Induces Pleiotropic Anti-Myeloma Activity in Vitro and In Vivo.
    Tai, Yu-Tzu
    Kim, Kihyun
    Li, Xian-Feng
    Fulciniti, Mariateresa
    Song, Weihua
    Nahar, Sabikun
    Burger, Peter
    Rumizen, Mathew J.
    Podar, Klaus
    Chauhan, Dharminder
    Hideshima, Teru
    Schlossman, Robert L.
    Munshi, Nikhil C.
    Richardson, Paul
    Clark, Ann
    Ogden, Janet
    Andreas, Goutopoulos
    Rastelli, Luca
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1480 - 1480
  • [47] Clinical activity of the oral MEK1/MEK2 inhibitor GSK1120212 in pancreatic and colorectal cancer
    Messersmith, W. A.
    Falchook, G. S.
    Fecher, L. A.
    Gordon, M. S.
    Vogelzang, N. J.
    DeMarini, D. J.
    Peddareddigari, V. G.
    Xu, Y.
    Bendell, J. C.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [48] Functional redundancy of the kinases MEK1 and MEK2: Rescue of the Mek1 mutant phenotype by Mek2 knock-in reveals a protein threshold effect
    Aoidi, Rifdat
    Maltais, Annie
    Charron, Jean
    SCIENCE SIGNALING, 2016, 9 (412)
  • [49] Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1
    Lee, Ki Won
    Kang, Nam Joo
    Rogozin, Evgeny A.
    Kim, Hong-Gyum
    Cho, Yong Yeon
    Bode, Ann M.
    Lee, Hyong Joo
    Surh, Young-Joon
    Bowden, G. Tim
    Dong, Zigang
    CARCINOGENESIS, 2007, 28 (09) : 1918 - 1927
  • [50] Cellular and Molecular Mechanisms of MEK1 Inhibitor-Induced Cardiotoxicity
    Beck, Tyler C.
    Arhontoulis, Dimitrios C.
    Morningstar, Jordan E.
    Hyams, Nathaniel
    Stoddard, Andrew
    Springs, Kendra
    Mukherjee, Rupak
    Helke, Kris
    Guo, Lilong
    Moore, Kelsey
    Gensemer, Cortney
    Biggs, Rachel
    Petrucci, Taylor
    Kwon, Jennie
    Stayer, Kristina
    Koren, Natalie
    Harvey, Andrew
    Holman, Heather
    Dunne, Jaclyn
    Fulmer, Diana
    Vohra, Ayesha
    Mai, Le
    Dooley, Sarah
    Weninger, Julianna
    Vaena, Silvia
    Romeo, Martin
    Muise-Helmericks, Robin C.
    Mei, Ying
    Norris, Russell A.
    JACC: CARDIOONCOLOGY, 2022, 4 (04): : 535 - 548
12345